Australian Clinical Labs (ASX:ACL) Cash-to-Debt : 0.07 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Australian Clinical Labs's cash to debt ratio for the quarter that ended in Dec. 2024 was 0.07.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Australian Clinical Labs couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Australian Clinical Labs's Cash-to-Debt or its related term are showing as below:

ASX:ACL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04 Med: 0.08 Max: 0.17
Current: 0.07

During the past 5 years, Australian Clinical Labs's highest Cash to Debt Ratio was 0.17. The lowest was 0.04. And the median was 0.08.

ASX:ACL's Cash-to-Debt is ranked worse than
92.13% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.97 vs ASX:ACL: 0.07

Australian Clinical Labs Cash-to-Debt Historical Data

The historical data trend for Australian Clinical Labs's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Australian Clinical Labs Cash-to-Debt Chart

Australian Clinical Labs Annual Data

Trend

Dec20

Jun21

Jun22

Jun23

Jun24

Cash-to-Debt

0.04

0.12

0.10

0.06

0.09

Australian Clinical Labs Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial				0.05	0.06	0.08	0.09	0.07

Competitive Comparison of Australian Clinical Labs's Cash-to-Debt

For the Diagnostics & Research subindustry, Australian Clinical Labs's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australian Clinical Labs's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Australian Clinical Labs Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Australian Clinical Labs's Cash to Debt Ratio for the fiscal year that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	26.136	/	(104.709	+	204.19)
	=	0.08

Australian Clinical Labs's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	21.565	/	(110.697	+	204.622)
	=	0.07

Australian Clinical Labs (ASX:ACL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Australian Clinical Labs Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Australian Clinical Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168

Website

https://www.clinicallabs.com.au

Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.

Australian Clinical Labs Headlines

No Headlines